Bridget K Marcellino

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1720442/publications.pdf

Version: 2024-02-01

1040056 940533 26 276 9 16 citations g-index h-index papers 27 27 27 421 docs citations times ranked citing authors all docs

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Plasma hemoglobin in COVID-19: authors' reply. Annals of Hematology, 2021, 100, 2127-2127. | 1.8 | O |
| 2 | Coombs-negative hemolytic anemia and elevated plasma hemoglobin levels in COVID-19. Annals of Hematology, 2021, 100, 833-835. | 1.8 | 11 |
| 3 | Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies. HemaSphere, 2021, 5, e549. | 2.7 | 29 |
| 4 | Recent advances in prognostication and treatment of polycythemia vera. Faculty Reviews, 2021, 10, 29. | 3.9 | 2 |
| 5 | Clinical Course of Cancer Patients With COVID-19: A Retrospective Cohort Study. JNCI Cancer Spectrum, 2021, 5, pkaa085. | 2.9 | 15 |
| 6 | Development of an MDM2 Degrader for Treatment of Acute Leukemias. Blood, 2021, 138, 1866-1866. | 1.4 | 3 |
| 7 | Alternatives to intensive treatment in patients with AML. Clinical Advances in Hematology and Oncology, 2021, 19, 526-535. | 0.3 | 1 |
| 8 | A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post-Âpolycythemia vera/essential thrombocythemia myelofibrosis (post-ÂPV/ET MF). Leukemia Research, 2020, 88, 106272. | 0.8 | 25 |
| 9 | Myeloid Sarcoma of the Testis in Children: Clinicopathologic and Immunohistochemical Characteristics With KMT2A (MLL) Gene Rearrangement Correlation. Applied Immunohistochemistry and Molecular Morphology, 2020, 28, 501-507. | 1.2 | 7 |
| 10 | Correlation Analysis Between the Expression of MEF2B, and Germinal Center and Nongerminal Center Markers in Diffuse Large B-Cell Lymphoma. Applied Immunohistochemistry and Molecular Morphology, 2020, 28, e63-e64. | 1.2 | 2 |
| 11 | Activation of cytotoxic T cell population and inversion of CD4:CD8 ratio as manifestations of cellular immune response in SARS-COV-2 infection. Journal of Hematopathology, 2020, 13, 197-199. | 0.4 | 8 |
| 12 | Prevalence of Cytopenia in the General Population—A National Health and Nutrition Examination Survey Analysis. Frontiers in Oncology, 2020, 10, 579075. | 2.8 | 3 |
| 13 | Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin. Blood Advances, 2020, 4, 5735-5744. | 5.2 | 21 |
| 14 | The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 415-421. | 0.4 | 38 |
| 15 | Acquired amegakaryocytic thrombocytopenia as a rare cause of thrombocytopenia during pregnancy. BMJ Case Reports, 2019, 12, e230361. | 0.5 | 1 |
| 16 | A Novel t(1;9)(p36;p24.1) JAK2 Translocation and Review of the Literature. Acta Haematologica, 2019, 142, 105-112. | 1.4 | 5 |
| 17 | A Rare Presentation of HIV-Negative Plasmablastic Lymphoma: A Diagnostic Dilemma. Case Reports in Hematology, 2019, 2019, 1-4. | 0.4 | 4 |
| 18 | Eosinophilia in acute myeloid leukemia: Overlooked and underexamined. Blood Reviews, 2019, 36, 23-31. | 5.7 | 14 |

| # | Article | IF | CITATION |
|----|--|------|----------|
| 19 | SLAM dunk for myelofibrosis?. Blood, 2019, 134, 789-791. | 1.4 | 0 |
| 20 | Management of advanced phase myeloproliferative neoplasms. Clinical Advances in Hematology and Oncology, 2019, 17, 405-411. | 0.3 | 7 |
| 21 | Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53. Blood Advances, 2018, 2, 3581-3589. | 5.2 | 49 |
| 22 | Dose-Adjusted Intensive Chemotherapy Is Safe and Tolerable in Older Patients with Ph-Negative Acute Lymphoblastic Leukemia. Blood, 2018, 132, 5158-5158. | 1.4 | 1 |
| 23 | Dietary Restriction and Glycolytic Inhibition Reduce Proteotoxicity and Extend Lifespan via NHR-49. Current Neurobiology, 2018, 9, 1-7. | 1.0 | 2 |
| 24 | Distinguishing autoimmune myelofibrosis from primary myelofibrosis. Clinical Advances in Hematology and Oncology, 2018, 16, 619-626. | 0.3 | 13 |
| 25 | Pharmacotherapy of Myelofibrosis. Drugs, 2017, 77, 1549-1563. | 10.9 | 5 |
| 26 | Neuroprotection by dietary restriction and the PPAR transcription complex. Translational Neuroscience, 2012, 3, . | 1.4 | 4 |